Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia. | Zhou et al. Journal of Hematology Oncology 2011 4 27 http content 4 1 27 JOURNAL OF HEMATOLOGY ONCOLOGY LETTER TO THE EDITOR Open Access Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia Fang Zhou Linfu Ge Zhe Yu Yuan Fang and Fansheng Kong Abstract Objective To evaluate the efficacy of enhanced intensive immuno-suppressive therapy with umbilical cord blood support for severe aplastic anemia SAA . Methods A total of 25 patients with SAA received enhanced intensive immuno-suppressive therapy and a cord blood transfusion. Therapy protocol Anti-thymocyte globulin ATG mg kg-d X 5d Cyclophosphamide 50 mg kg-d X 2d cyclosporin A CsA maintenance therapy. Result 25 patients were enrolled. 18 underwent a complete recovery 4 made significant improvements 1 did not respond and 2 died. Therefore the efficacy rate was 88 . The median follow-up time was 35 months range 13-47 months and the 3-year overall survival rate was 92 . Patients rapidly achieved reconstitution of hematopoiesis. The median time to neutrophil ANC X 109 L was 18 days range 8-36 platelets 20 X 109 L was 34 days range 12-123 and Hb 100 g L 95 dyas range 35-173 . Conclusion Enhanced intensive immuno-suppressive therapy with umbilical cord blood support may be an effective option for SAA therapy. To the Editor Severe aplastic anemia SAA has a high mortality rate 1 . High-dose cyclophosphamide CTX treatment for SAA provides some benefit however the recovery of hematopoiesis is slow and some studies have demonstrated high treatment-related mortality rates. Therefore the toxic side effects of high-dose CTX . hemorrhagic cystitis cannot be ignored. Intensive immunosuppressive therapy such as combined anti-thymocyte globulin ATG and cyclosporine CSA has an average onset of efficacy of 3-7 months and an efficacy rate of 60-80 . Before the onset of efficacy patients are susceptible to severe .
